NEXT Oncology Barcelona

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Colorectal cancer2 trials
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Thyroid cancer1 trial

Phase

• Phase 1/23 trials
• Phase 12 trials

Status

• Completed2 trials
• Not yet recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Alentis Therapeutics AG1 trial
• Daiichi Sankyo1 trial
• Famewave Ltd.1 trial
• TOLREMO therapeutics AG1 trial
• Vividion Therapeutics, Inc.1 trial

Running trials

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

  NCT06403436· Phase 1· TOLREMO therapeutics AG· Source

• Completed

  A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

  NCT04731467· Phase 1/2· Famewave Ltd.· Source